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Abstract
In the phase III study RESONATE, ibrutinib reduced the risk of progression and improved overall 
survival versus ofatumumab in previously treated patients with CLL/SLL. In this novel analysis of 
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patient well-being including patient-reported outcomes, ibrutinib reduced disease burden while 
preserving parameters of hematologic and immunologic function in RESONATE. These results 
suggest that ibrutinib can improve quality of life while prolonging survival.
Background: Ibrutinib compared with ofatumumab significantly improves progression-free and 
overall survival in patients with previously treated chronic lymphocytic leukemia/small 
lymphocytic lymphoma (CLL/SLL).
Patients and Methods: Measures of well-being were assessed in RESONATE, where 
previously treated patients with CLL/SLL were randomized to receive ibrutinib 420 mg/day (n = 
195) or ofatumumab (n = 196) for up to 24 weeks. Endpoints included hematologic function, 
Functional Assessment of Chronic Illness Therapy—Fatigue (FACIT-F), disease-related 
symptoms, European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaires Core 30 (EORTC QLQ-C30), and medical resource utilization.
Results: With up to 24 months’ follow-up (median, 16.4 months), 79% of cytopenic patients 
showed sustained hematologic improvement (82% with improved platelet count, 69% with 
improved hemoglobin) on ibrutinib versus 43% on ofatumumab (P < .0001). Higher rates of 
clinically meaningful improvement were demonstrated with ibrutinib versus ofatumumab for 
FACIT-F and EORTC global health. Greater improvement was observed in disease-related weight 
loss, fatigue, night sweats, and abdominal discomfort with ibrutinib versus ofatumumab. 
Hospitalizations in the first 30 days occurred less frequently with ibrutinib than ofatumumab 
(0.087 vs. 0.184 events/patient; P = .0198). New-onset diarrhea was infrequent with ibrutinib after 
the first 6 months (47% at ≤6 months vs. 5% at 12-18 months). With ibrutinib, grade ≥ 3 
hypertension occurred in 6%, grade ≥ 3 atrial fibrillation in 4%, major hemorrhage in 2%, and 
tumor lysis syndrome in 1% of patients.
Conclusion: Ibrutinib led to significant improvements in hematologic function and disease 
symptomatology versus ofatumumab, and can restore quality of life while prolonging survival in 
relapsed/refractory CLL/SLL.
Keywords
Bruton’s tyrosine kinase; Disease-related symptoms; Fatigue; Quality of life; Relapsed/refractory 
CLL/SLL
Introduction
Chronic lymphocytic leukemia (CLL) is a common leukemia in the United States1; 
manifestations of progressive disease and indications for treatment include 
lymphadenopathy, splenomegaly, bone marrow failure (anemia, thrombocytopenia), and 
significant disease-related symptoms.2 CLL complications and toxicities associated with 
therapy can profoundly impact quality of life (QoL) and well-being, particularly in older 
patients.3,4 Patient-reported outcome (PRO) scores of emotional well-being tend to be lower 
in patients with CLL than in patients with other malignancies,4 and studies have shown 
significant QoL improvements with effective CLL treatment including chemotherapy, as 
well as in prior small non-randomized studies with ibrutinib.5–11
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Ibrutinib, an oral, first-in-class, once-daily inhibitor of Bruton’s tyrosine kinase, has shown 
substantial single-agent efficacy and tolerability in CLL/small lymphocytic lymphoma 
(SLL).12–15 In the phase III study (RESONATE) comparing ibrutinib with ofatumumab in 
previously treated patients with CLL/SLL, ibrutinib reduced risk of progression as assessed 
by an independent review committee (IRC) by 78% and risk of death by 57% with a median 
follow-up of 9.4 months at primary analysis.14 Measures of patient well-being including 
parameters of hematologic and immunologic function, and QoL are reported from the 
RESONATE study. These data are the first to show sustained improvements in PRO, 
hematologic function, and disease symptoms associated with ibrutinib in a randomized 
study.
Patients and Methods
Patients
Patients with CLL/SLL who had received ≥ 1 prior therapy and had active disease with an 
indication for therapy per International Workshop on Chronic Lymphocytic Leukemia 
(iwCLL) guidelines were enrolled.2 Eligibility criteria have been described previously.14 All 
patients provided written informed consent.
Study Design
Patients were randomized to once-daily oral ibrutinib (420 mg) or intravenous ofatumumab 
as previously described.14 Ofatumumab data beyond 6 months were limited by maximum 
treatment duration (6 months) and a median progression-free survival (PFS) of 8.1 months,14 
affecting the efficacy and safety variables in this updated analysis. Further, 122 patients 
randomized to ofatumumab had crossed over to ibrutinib after disease progression (PD).
Study Endpoints
PFS, overall survival (OS), and overall response rate (ORR) have been previously reported.
2,14
 Secondary efficacy endpoints include sustained hematologic improvement (see 
Supplemental Methods [in the online version] for definition) in patients with cytopenia(s) at 
baseline, and PRO as measured by Functional Assessment of Chronic Illness Therapy-
Fatigue (FACIT-F). FACIT-F is a validated instrument that assesses tiredness, weakness, and 
difficulty conducting daily activities owing to fatigue. Scores range from 0 to 52, with high 
scores indicating less fatigue.16 A change in FACIT-F score of ≥ 3 points17 was considered 
clinically meaningful. FACIT-F forms and other PRO instruments were generally completed 
by patients prior to any study procedures. Per protocol, patients were not required to 
complete the questionnaire following PD/crossover or after completing treatment if assigned 
to the ofatumumab arm.
Prespecified exploratory endpoints included improvement of investigator-assessed disease-
related symptoms (National Cancer Institute Common Terminology Criteria for Adverse 
Events, version 4.0 [CTCAE] grade decrease of ≥ 1 post-baseline, reported for ≥ 2 
consecutive assessments of weight loss, fatigue, fever, night sweats, abdominal discomfort 
owing to splenomegaly, and/or anorexia), PRO as measured by European Organization for 
Research and Treatment of Cancer Quality of Life Questionnaires Core 30 (EORTC QLQ-
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C30; clinically meaningful change defined as > 10 points18), and medical resource 
utilization associated with therapy including number of hospitalizations, any blood product 
transfusions (red blood cells, platelets, whole blood), and use of any hematopoietic growth 
factors. Compliance rates for FACIT-F and EORTC QLQ-C30 questionnaire completion 
were monitored (see Supplemental Table 1 in the online version).
To evaluate disease burden, lymph nodes and splenic enlargement were quantified by IRC-
assessed computed tomography; reduction was defined per iwCLL criteria.2 The effect of 
ibrutinib versus ofatumumab on white blood cell count and differential was evaluated over 
time. Lymphocyte subsets (B cells, T cells, natural killer [NK] cells [see Supplemental 
Methods in the online version]) were evaluated by flow cytometry for patients with baseline 
samples. Serum immunoglobulin levels (IgA, IgG, IgM) were quantitated.
Adverse event (AE) severity was graded using CTCAE, except for hematologic toxicities, 
which were graded based on iwCLL criteria.2 The treatment-emergent period for AE 
collection was defined as the time from the first dose of study drug to 30 days after the last 
dose of study drug or initiation of subsequent antineoplastic therapy, whichever comes first. 
Treatment-emergent AEs were summarized by time to event onset and by prevalence. (See 
Supplemental Methods in the online version, for details regarding statistical methods used in 
the study.)
Results
Baseline Characteristics and Patient Disposition
As described previously, 391 patients with previously treated CLL/SLL were randomized to 
ibrutinib (n = 195; median 3 prior therapies [range, 1-12]) or ofatumumab (n = 196; median 
2 prior therapies [range, 1-13]).14 Baseline characteristics were balanced across both 
treatment groups and have been previously published.14 In general, the enrolled population 
was elderly (over 20% of patients were aged ≥ 75 years), and comorbidities were common 
(such as reduced creatinine clearance and cytopenias at baseline). The median follow-up was 
9.4 months at the time of primary analysis. This analysis reflects data at a median follow-up 
of 15.0 months (16.4 for ibrutinib, 11.9 for ofatumumab; up to 24 months maximum).
Sustained Hematologic Improvement
In cytopenic patients treated with ibrutinib, 69% showed sustained improvement in 
hemoglobin, 82% in platelets, and 68% in absolute neutrophil count, all of which were 
statistically significant versus changes with ofatumumab (Table 1). Of ibrutinib patients with 
any baseline cytopenia, 79% showed sustained improvement in blood counts with this longer 
follow-up compared with 69% at the primary analysis, where it was significantly higher 
versus ofatumumab (43%; P < .0001). Figure 1A, B demonstrates early improvement in 
median hemoglobin and platelet levels, respectively, which were sustained during the first 6 
months in patients in both treatment arms with baseline cytopenias, and through 16 months 
on the ibrutinib arm.
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Patient-Reported Outcomes
FACIT-F.—Baseline FACIT-F scores for ibrutinib and ofatumumab were similar (mean, 35.7 
vs. 34.5, respectively). More patients achieved clinically meaningful improvement in FACIT-
F with ibrutinib versus ofatumumab (56% vs. 43%; odds ratio [OR], 1.69; P = .0101); 
clinically meaningful improvement with ibrutinib was sustained through 60 weeks of follow-
up (Figure 1C).
EORTC QLQ-C30.—At baseline, ibrutinib and ofatumumab patients had similar mean 
scores for EORTC QLQ-C30 global health status (60.0 vs. 58.3, respectively). Greater 
improvement in global health status mean score was seen at 24 weeks with ibrutinib versus 
ofatumumab (9.0 vs. 5.8, respectively) (see Supplemental Table 2 in the online version). Of 
the 15 EORTC domains assessed at baseline, nausea/vomiting, diarrhea, and constipation 
had the lowest severity, and global health status had the highest impairment. At week 24, 
patients treated with ibrutinib improved on 13 (all but nausea/vomiting and diarrhea) versus 
12 domains (all but cognitive functioning, pain, or constipation) with ofatumumab (see 
Supplemental Table 2 in the online version). A significantly greater proportion of patients on 
ibrutinib compared with ofatumumab reported an improvement in cognitive functioning, 
including concentration and recall (32% vs. 20%; P = .008). Overall, the mean change in 
scores from baseline to week 24 across the EORTC QLQ-C30 domains appeared 
comparable between treatment arms. An improvement in the EORTC Fatigue Subscale score 
from baseline to week 24 was seen with ibrutinib (n = 117; median 11-point improvement), 
whereas no improvement was seen with ofatumumab (n = 87; median 0-point improvement).
Reduction in Disease Burden
Disease burden was assessed by independent review prior to discontinuation for the primary 
analysis with 9.4 months median follow-up, similar to the median PFS for the ofatumumab 
arm (8.1 months). At least a 50% reduction in lymph node size was observed more 
frequently with patients on ibrutinib versus ofatumumab (92% vs. 14%; P < .0001) (Figure 
2A); the median time to reduction was 2.6 versus 5.3 months with ibrutinib and 
ofatumumab, respectively. Reduction in spleen size was more common in ibrutinib-treated 
than ofatumumab-treated patients (85% vs. 54%; P < .0001) (Figure 2B); the median time to 
reduction was 2.6 months with both ibrutinib and ofatumumab. These improvements are 
consistent with recently published updates to PFS and OS showing continued benefit for 
patients randomized to ibrutinib (median follow-up 19 months: PFS, hazard ratio [HR], 
0.106; P < .0001; 18-month landmark OS, HR, 0.361; 95% confidence interval [CI], 
0.208-0.628).14,19
Disease-Related Symptoms and Medical Resource Utilization
Consistent with findings at the primary analysis, improvement in disease-related symptoms 
were assessed by investigators more frequently with ibrutinib than with ofatumumab for 
weight loss (100% vs. 87%), fatigue (79% vs. 64%), night sweats (89% vs. 77%), abdominal 
pain/discomfort (96% vs. 75%), and anorexia (100% vs. 64%), but not fever (88% vs. 
100%). Hospitalizations in the first 30 days occurred less frequently with ibrutinib than 
ofatumumab (0.087 vs. 0.184 events/patient20; P = .0198); however, no significant 
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differences were observed through 6 months. Growth factor usage after day 30 occurred 
slightly more frequently with ofatumumab than ibrutinib (5%-9% vs. 2%-4% each month 
through month 6, respectively). Transfusion rates with ibrutinib and ofatumumab (30% vs. 
24%) were not notably different through 6 months.
White Blood Cell Count, Lymphocyte Counts, and Serum Immunoglobulin Levels
In both arms, the white blood cell differential trended to normal with an increase in the 
proportion of neutrophils and a decrease in lymphocyte proportions versus baseline (see 
Supplemental Figure 1A in the online version). In the ibrutinib arm, elevated baseline 
absolute lymphocyte count (ALC) declined over time to a median of 50% below baseline at 
24 weeks and continued to decrease to normal (< 4 × 109/L) at later time points (after the 
expected initial transient increase with ibrutinib) (see Supplemental Figure 1B, C in the 
online version). Supplemental Table 3 (in the online version) shows distributions of peak 
ALC in ibrutinib-treated patients relative to baseline ALC.
The primarily malignant B cell counts were stable with ibrutinib and decreased with 
ofatumumab at week 12 (Figure 3 and Supplemental Figure 2 [in the online version]). After 
week 12, B cell counts in the ibrutinib arm also decreased significantly over time, with 
median count approaching the upper limit of normal at week 72. Median T cell (including 
CD3+, CD4+, and CD8+ subsets) and NK cell counts remained within the limits of normal 
throughout testing, whereas the relative proportion of T cells (including CD4+ and CD8+ 
subsets) and NK cells progressively increased over time. For 57 patients with available 
baseline samples, median counts for CD3+ and CD4+ T cells (but not CD8+) and NK cells 
were significantly decreased at week 72, remaining above the lower limits of normal (LLN). 
The median regulatory T cell counts significantly decreased over time on ibrutinib, dropping 
from the upper limit of normal to the LLN (see Supplemental Figure 3 in the online version).
Analysis of serum Immunoglobulin levels (excluding the 32% and 22% of ibrutinib and 
ofatumumab patients on intravenous Immunoglobulin replacement) showed a significant 
increase in IgA levels with ibrutinib, rising to the LLN at week 12, which was maintained 
through week 72. Median IgG levels were stable with up to 1.4 years on ibrutinib, rising to 
the LLN at week 72. Median IgM level changes were nonsignificant and varied over time 
from just above to just below the LLN from week 36 to week 60 (Figure 4). For those with 
baseline levels below the LLN, a similar increase was observed for IgA without significant 
decrement in IgG or IgM over time (data not shown).
Adverse Events
Most AEs were grade 1 in severity. The most frequently observed AEs among ibrutinib 
patients at any time were diarrhea (37% grade 1, 10% grade 2, 4% grade 3), fatigue (19% 
grade 1, 12% grade 2, 3% grade 3), and nausea (24% grade 1, 6% grade 2, 2% grade 3), of 
which none were grade 4. Except for diarrhea (all grade), rates of common AEs in the first 6 
months were similar between the treatment arms (Figure 5A). New onset of these events was 
less frequent after the first 6 months such as diarrhea (all grades) rates, which declined over 
time from 47% at 0 to 6 months to 5% at 12 to 18 months (Figure 5B).
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With prolonged ibrutinib treatment, the most frequent grade ≥ 3 AEs at any time were 
neutropenia (18%), pneumonia (11%), hypertension (6%), and thrombocytopenia (6%). The 
incidences of grade ≥ 3 infections and cytopenias were similar for ibrutinib and ofatumumab 
during the first 6 months of therapy (Figure 5A). Except for hypertension, the incidences of 
other frequent grade ≥ 3 AEs decreased or were similar over time (Figure 5C). Prevalence of 
grade ≥ 3 infections at any time was 30% for ibrutinib and 20% for ofatumumab (see 
Supplemental Figure 4 in the online version). Exposure-adjusted all-grade infection rate 
with ibrutinib versus ofatumumab was 14.7 versus 18.4 per 100 patient-months (grade ≥ 3 
was 2.5 vs. 5.7, respectively). Upper respiratory tract infection was the most common all-
grade infection for both the overall ibrutinib cohort (24%) and those with compromised Ig 
status at baseline (25% for IgA < LLN, 26% for IgG < LLN).
Atrial fibrillation occurred at any time in 13 (7%) patients, including grade ≥ 3 in 7 (4%) 
patients, resolving in 6 of 7 patients and leading to ibrutinib discontinuation in 1 patient, 
who was subsequently noted to have PD; the majority of grade ≥ 3 atrial fibrillation events 
were reported in the first 6 months of ibrutinib therapy. Major hemorrhage occurred in 4 
patients (2%): grade 2 subdural hematoma, grade 3 post-procedural hemorrhage, grade 3 
spontaneous hematoma, and grade 4 subdural hematoma (see Supplemental Table 4 in the 
online version). Tumor lysis syndrome occurred 5 and 11 days after ibrutinib discontinuation 
in 2 patients with PD (study days 534 and 242, respectively) who had not yet started any 
next line therapy for CLL.
At a median treatment duration of 16 months for ibrutinib versus 5 months for ofatumumab, 
13 ibrutinib patients and 7 ofatumumab patients discontinued study drug primarily due to 
AEs. In total, 23 and 16 patients, respectively, had AEs associated with discontinuation, 
most frequently pneumonia; among patients who discontinued ibrutinib due to AEs, longer 
duration of therapy appears to be associated with increased time to progression (see 
Supplemental Table 5 in the online version). AEs leading to ibrutinib discontinuation 
occurred in 12 of 195, 9 of 172, 1 of 159, and 1 of 39 patients at 0 to 6, 7 to 12, 13 to 18, and 
19 to 24 months, respectively. AEs leading to ibrutinib dose reduction occurred in 7 of 195, 
4 of 172, and 2 of 159 patients at 0 to 6, 7 to 12, and 13 to 18 months, respectively.
Discussion
Ibrutinib is a selective first-in-class irreversible inhibitor of Bruton’s agammaglobulinemia 
tyrosine kinase with an important role in multiple cellular functions including B-cell antigen 
receptor signaling. A high frequency of durable responses and acceptable safety associated 
with ibrutinib in the previously treated population with CLL has been demonstrated in the 
RESONATE study with enhanced PFS, OS, and ORR as compared with ofatumumab, 
including in high-risk subgroups.14,19 This report demonstrates that in addition to its known 
efficacy, prolonged administration of ibrutinib confers patients additional benefits as 
assessed by multiple measures of well-being, including preservation of parameters of 
hematologic and immunologic function. At a median of 16.4 months follow-up, the present 
data are among the first reports from a randomized phase III study to demonstrate significant 
improvement in hematologic and immunologic parameters in parallel with QoL 
improvements. In the majority of patients with baseline cytopenias, ibrutinib led to early and 
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sustained platelet and hemoglobin improvements (82% and 69%, respectively), which were 
markedly better than for the patients randomized to ofatumumab.
With up to 2 years of follow-up, the positive hematologic effects of ibrutinib resulted in 
sustained normalization of hemoglobin in 69% and of platelet count in 82% of patients with 
baseline anemia and thrombocytopenia, respectively. Transient increase followed by 
sustained decrease in percentage of lymphocytes over time is expected given the known 
pharmacodynamic ‘redistribution’ phenomenon of B-cell receptor inhibitor treatment-related 
lymphocytosis. Malignant B cell counts decreased dramatically with ibrutinib and 
approached normal limits by week 72, and median CD4+, CD8+, and NK cell counts 
remained within normal limits throughout treatment. Reduction in regulatory T cell counts 
to the LLN was observed in ibrutinib-treated patients consistent with preclinical studies of 
ibrutinib and other clinical data sets.21–23 Future analyses discriminating normal from 
neoplastic B cells would be beneficial to ascertain any modulatory effects of ibrutinib. An 
increase in IgA levels was also observed with ibrutinib over time, without significant 
decrement in IgG or IgM.
In a National Institutes of Health study of patients with CLL ≥ 65 years of age or with TP53 
aberration, the infection rate overall was lower in treatment-naive (TN) versus relapsed/
refractory (R/R) patients, but rates declined over time in both TN and R/R populations24; 
data that suggest clinically relevant improvement in humoral immunity with ibrutinib 
treatment. In an integrated analysis of patients from the RESONATE and RESONATE-2 
(ibrutinib vs. chlorambucil in older patients with TN CLL/SLL) trials, infection rates were 
also shown to decrease with time on ibrutinib.25 Although the decreased incidence of 
various infections over time seen during ibrutinib treatment in this and other reports may 
reflect these positive hematologic effects on lymphocytes and immunoglobulin levels, future 
detailed analyses of these infections may be warranted, given recent descriptions of 
opportunistic infections occurring during ibrutinib treatment.26,27
PROs, including health-related QoL, are increasingly assessed in clinical trials as a measure 
of effectiveness and to help with decision-making. Analysis of FACIT-F outcomes showed 
that a clinically meaningful improvement from baseline was reached in < 24 weeks with 
ibrutinib and ofatumumab, with mean improvement sustained through 60 weeks of follow-
up on ibrutinib. Similarly, fatigue was improved as measured with the EORTC fatigue 
subscale PRO as well as investigator-assessed disease-related symptoms. Additionally, 100% 
of patients treated with ibrutinib experienced improvements in weight loss and anorexia. The 
magnitude of improvement (mean change from baseline to week 24) in EORTC QLQ-C30 
was greater with ibrutinib compared with ofatumumab for domains including global health 
status, physical functioning, fatigue, dyspnea, and constipation, whereas the improvement 
was greater with ofatumumab for role functioning, social functioning, and appetite loss. 
When considering the threshold for clinically meaningful improvement, only dyspnea was 
improved with ibrutinib (mean change, −11.0) and appetite loss with ofatumumab (mean 
change, −13.0). Notably, comparative data between treatment groups are limited due to the 
ofatumumab arm fixed duration of treatment (maximum 6 months) and relatively short PFS 
(median, 8.1 months),14 but the overall effects of ibrutinib on QoL reflect clinically 
meaningful gains that were sustained throughout the 60 weeks of follow-up. Irrespective of 
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this disparity in drug exposure time, the majority of positive ibrutinib benefits were also 
observed at the time of the primary analysis when treatment durations were comparable.14 
For safety and medical resource utilization data, this imbalance in follow-up would generally 
favor ofatumumab. Despite this, medical resource utilization as a prespecified exploratory 
endpoint, including hospitalizations in the first 30 days and growth factor usage after day 30, 
was higher in the ofatumumab group versus the ibrutinib group. Cost implications were not 
analyzed, although one recent real-world analysis of front line CLL treatment showed 
reduced medical resource utilization and reduced costs of care are incurred with ibrutinib 
compared with chemoimmunotherapy.28 That analysis did not evaluate pharmacy costs, and 
it remains unknown how these will contribute to the balance of costs for ibrutinib versus 
chemoimmunotherapy options. Such evaluations will be of further interest in the real-world 
setting.
No new safety signals were identified in this study versus earlier phase II studies,12 and new 
events of diarrhea, certain infections, and cytopenias, including grade ≥ 3 events, were 
observed less frequently over time. These data suggest that, except for the appearance of 
grade 3 hypertension, the likelihood of new onset treatment-emergent AEs may be reduced 
with long-term ibrutinib therapy.
Conclusion
Clinical data describing psycho-oncologic endpoints in studies of patients with CLL treated 
with new small targeted molecules or biologics are sparse. These novel RESONATE 
findings are among the first randomized data to assess multiple measures of overall patient 
well-being with treatment, including PROs, disease burden, hematologic function, and 
benefits to patients with regard to disease management and reduced requirement for 
supportive care. A survival benefit with ibrutinib, together with sustained improvements in 
hematologic endpoints and patient-reported outcomes, suggest that ibrutinib can improve 
QoL while prolonging survival.
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Clinical Practice Points
• Complications associated with CLL and toxicities of therapy can profoundly 
affect QoL and patient well-being.
• These analyses of RESONATE are the first to show significant psycho-
oncologic improvements with ibrutinib in R/R CLL, in addition to the known 
benefits of longer PFS, OS, and improved ORR compared with anti-CD20 
therapy.
• Sustained hematologic improvement, clinically meaningful improvement in 
fatigue and overall QoL, and fewer early hospitalizations were observed with 
ibrutinib compared with ofatumumab while maintaining a reduction in disease 
burden.
• No new safety signals with ibrutinib were identified in this study, and the 
onset of treatment-emergent AEs decreased over time.
• Hematologic function, QoL, and overall patient well-being are a vital part of 
medical decision-making in addition to the clinical benefits of prolonged 
survival in patients with R/R CLL/SLL.
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Figure 1. 
Change Over Time by Treatment Arm in Median Hgb Levels (A), Median Platelet Count 
(B), and Improvement in FACIT-F Including Long-Term Extended Follow-Up (C)
Abbreviations: FACIT-F = Functional Assessment of Chronic Illness Therapy-Fatigue; Hgb 
= hemoglobin.
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Figure 2. 
Reduction in Lymph Nodes* (A) and Splenic Enlargement† (B) (Primary Analysis)
*Sum of the products of multiple lymph nodes (as evaluated by computed tomography 
scans) or the longest diameter of one target lymph node. †Patients who experienced 
resolution of splenic enlargement by IRC are considered to have 100% reduction.
Abbreviations: IRC = independent review committee; NE = not evaluable; PD = progressive 
disease; PR = partial response; PR-L = PR with lymphocytosis; SD = stable disease.
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Figure 3. 
Absolute Counts Over Time of CD3+ (A), CD4+ (B), CD8+ (C), CD19+ (D), and 
CD16/56+ (E) Cells. ULN and LLN (× 109/L): CD3+, 0.723-2.737; CD4 + , 0.404-1.612; 
CD8+, 0.22-1.129; CD19+ , 0.08-0.724; and CD16/56+, 0.084-0.724. In Each Chart, ULN 
and LLN are Shown by Dashed Lines (With Axis Breaks); Only Uln is Shown for CD19+ 
Cells
Abbreviations: LLN = lower limit of normal; ULN = upper limit of normal.
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Figure 4. 
Median Levels* Over Time of IgA (A), IgG (B), and IgM (C). LLN for Baseline IgA, IgG, 
and IgM are 0.7 g/L, 5.65 g/L, and 0.4 g/L, Respectively, and are Shown by Dashed Lines
*Excluding patients on intravenous Ig.
Abbreviations: Ig = immunoglobin; LLN = lower limit of normal.
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Figure 5. 
Incidence of Common (≥ 20% for all Grade, ≥ 3% for Grade ≥ 3 at Any Time) Treatment-
Emergent Adverse Events that Occurred in the First 6 Months of Treatment in the Ibrutinib 
and Ofatumumab Arms (A), for all Grades by Time to Event Onset (B), and for Grades ≥ 3 
by Time to Event Onset in the Ibrutinib Arm (C). New Events are Presented Only During the 
Period of Time Where Event Began. Note, No Grade ≥ 3 Events Started at > 18 Months
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